BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12727930)

  • 1. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.
    Heaney AP; Fernando M; Melmed S
    J Clin Invest; 2003 May; 111(9):1381-8. PubMed ID: 12727930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.
    Heaney AP
    Pituitary; 2003; 6(3):153-9. PubMed ID: 14971739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
    Gruszka A; Kunert-Radek J; Pawlikowski M
    Neuro Endocrinol Lett; 2005 Feb; 26(1):51-4. PubMed ID: 15726020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.
    Heaney AP; Fernando M; Yong WH; Melmed S
    Nat Med; 2002 Nov; 8(11):1281-7. PubMed ID: 12379847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.
    Bogazzi F; Ultimieri F; Raggi F; Russo D; Vanacore R; Guida C; Viacava P; Cecchetti D; Acerbi G; Brogioni S; Cosci C; Gasperi M; Bartalena L; Martino E
    Eur J Endocrinol; 2004 Jun; 150(6):863-75. PubMed ID: 15191358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
    Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
    Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
    Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity.
    Takashima T; Fujiwara Y; Higuchi K; Arakawa T; Yano Y; Hasuma T; Otani S
    Int J Oncol; 2001 Sep; 19(3):465-71. PubMed ID: 11494023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas.
    Fernando MA; Heaney AP
    Mol Endocrinol; 2005 Dec; 19(12):3085-96. PubMed ID: 16020484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
    Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
    Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic fibroblastic growth factor stimulates prolactin secretion from human anterior pituitary adenomas without affecting adenoma cell proliferation.
    Atkin SL; Landolt AM; Jeffreys RV; Diver M; Radcliffe J; White MC
    J Clin Endocrinol Metab; 1993 Sep; 77(3):831-7. PubMed ID: 8370706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
    Emery MN; Leontiou C; Bonner SE; Merulli C; Nanzer AM; Musat M; Galloway M; Powell M; Nikookam K; Korbonits M; Grossman AB
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):389-95. PubMed ID: 16918962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
    Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotroph cell adenomas of the pituitary.
    Snyder PJ
    Endocr Rev; 1985; 6(4):552-63. PubMed ID: 2416559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells.
    Satoh T; Toyoda M; Hoshino H; Monden T; Yamada M; Shimizu H; Miyamoto K; Mori M
    Oncogene; 2002 Mar; 21(14):2171-80. PubMed ID: 11948400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.